VivoSim Labs, Inc. VIVS
Set alert
0.15 USD 0.00 -0.84%
At close · Nov 2
0.16 0.00 +1.57%
After hours · Nov 2, 7:35 PM ET
0.1499 Day range 0.1595
0.14 52-week range 3.40
- YTD
- -91.53%
- 1 year
- -94.32%
- Open
- 0.1549
- Prev close
- 0.1546
- Mkt cap
- 2.54M
- Vol
- 532.57K
- Avg vol
- 2.69M
- EPS
- -4.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1499
- High
- 0.1595
2Y chart
Signals (76)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 18, 2026 | 1 month ago |
| RSI: Oversold | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
| RSI: Oversold | Jul 16, 2026 | 3 months ago |
| RSI: Oversold | Jul 13, 2026 | 3 months ago |
| RSI: Oversold | Jul 7, 2026 | 3 months ago |
| RSI: Oversold | Jul 2, 2026 | 4 months ago |
| RSI: Oversold | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
| MACD: Sell Signal | May 12, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 15, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 10, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 7 months ago |
| RSI: Oversold | Mar 30, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 4, 2026 | 8 months ago |
| SMA: Bearish | Mar 3, 2026 | 8 months ago |
Newest 20 of 76.
Financials — quick view
VIVS Revenue — quarterly 18.00K
VIVS Net income — quarterly -1.34M
VIVS EPS — quarterly -0.25
News
- VivoSim Labs To Extend Its Human Tissue Platform Beyond Toxicology With Efficacy Testing Services Built On NAMkind Disease Models Of The Liver And Intestine
- VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Vivosim Labs Notes FDA's Direct Final Rule Clarifying That Non-Animal Methods Can Be Used Where Appropriate For Testing Safety Of Drugs And Biological Products For Human Use
- VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
- VivoSim Labs (NASDAQ:VIVS) vs. iSpecimen (NASDAQ:ISPC) Head to Head Comparison
- VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
- VivoSim Labs Plans To Develop Rat Liver Model To Complement Existing NAMkind Human Liver Platform And Expand Its Liver Toxicology Capabilities
- VivoSim Labs to Add Rat Liver Model to NAMkind Platform
- Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on VIVS — it syncs with the Stock Master app.